Titan Biotech (BOM:524717) ROCE %: 22.39% (As of Mar. 2026)


BOM:524717 Titan Biotech Ltd BOM:524717
50 GF Score
Price ₹389.10
GF Value ₹144.30
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Titan Biotech ROCE %?

Titan Biotech BOM:524717 +4.99% 50 ROCE % is 22.39% as of Mar. 2026. GuruFocus rates BOM:524717 with a GF Score™ of 50/100 and a GF Value™ of ₹144.30 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Titan Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was 22.39%.

Titan Biotech  (BOM:524717) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Titan Biotech ROCE % Related Terms

Titan Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Titan Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Biotech ROCE % Chart

Titan Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.37 27.94 25.81 17.10 22.67

Titan Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.01 21.17 22.19 25.43 22.39
BOM:524717
50GF Score
Titan Biotech Ltd BOM:524717
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Biotech ROCE % Calculation

Titan Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=390.884/( ( (1747.075 - 177.364) + (2138.848 - 259.627) )/ 2 )
=390.884/( (1569.711+1879.221)/ 2 )
=390.884/1724.466
=22.67 %

Titan Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=420.756/( ( (0 - 0) + (2138.848 - 259.627) )/ 1 )
=420.756/( ( 0 + 1879.221 )/ 1 )
=420.756/1879.221
=22.39 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 22.39% mean?
Titan Biotech (BOM:524717) has a ROCE % of 22.39% as of Mar. 2026.
Is Titan Biotech's ROCE % too high?
Titan Biotech's current ROCE % is 22.39%. Overall, Titan Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's ROCE % compare to VRTX and REGN?
Titan Biotech's ROCE % of 22.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Titan Biotech's current ROCE % is 22.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.30, compared to a current price of ₹389.10 — trading 169.6% above its estimated fair value. The current ROCE % is 22.39%. Titan Biotech's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current ROCE % is 22.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Titan Biotech (BOM:524717) Overvalued in 2026?

Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued. The current stock price of ₹389.10 is trading 169.6% above its estimated GF Value™ of ₹144.30. GuruFocus considers Titan Biotech to be Significantly Overvalued.

Key valuation signals for BOM:524717:

  • ROCE %: 22.39%
  • GF Value™: ₹144.30 vs. price of ₹389.10 (169.6% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Titan Biotech Business Description

Address Netaji Subhash Place, 903-909, 9th Floor, Bigjos Tower, New Delhi, IND, 110034
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
50GF Score

Get the complete analysis for BOM:524717

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹389.10
Price
₹144.30
GF Value